Review: Receptor Targeted Nuclear Imaging of Breast Cancer

Receptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2),...

Full description

Bibliographic Details
Main Authors: Simone U. Dalm, John Fred Verzijlbergen, Marion De Jong
Format: Article
Language:English
Published: MDPI AG 2017-01-01
Series:International Journal of Molecular Sciences
Subjects:
PET
ER
PR
Online Access:http://www.mdpi.com/1422-0067/18/2/260
id doaj-303354e73665479295684925dc3800d6
record_format Article
spelling doaj-303354e73665479295684925dc3800d62020-11-24T23:26:37ZengMDPI AGInternational Journal of Molecular Sciences1422-00672017-01-0118226010.3390/ijms18020260ijms18020260Review: Receptor Targeted Nuclear Imaging of Breast CancerSimone U. Dalm0John Fred Verzijlbergen1Marion De Jong2Department of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsDepartment of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsDepartment of Radiology & Nuclear medicine, Erasmus MC, Wytemaweg 80, 3015CN Rotterdam, The NetherlandsReceptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being investigated for this purpose. Expression of these targets is BC subtype dependent and information that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers, e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target expression can vary per subtype, but also during disease progression or under influence of treatment, radiotracers for selected imaging purposes should be chosen carefully.http://www.mdpi.com/1422-0067/18/2/260breast cancerreceptor targeted nuclear imagingSPECTPETGRPRSSTRERPRHER2
collection DOAJ
language English
format Article
sources DOAJ
author Simone U. Dalm
John Fred Verzijlbergen
Marion De Jong
spellingShingle Simone U. Dalm
John Fred Verzijlbergen
Marion De Jong
Review: Receptor Targeted Nuclear Imaging of Breast Cancer
International Journal of Molecular Sciences
breast cancer
receptor targeted nuclear imaging
SPECT
PET
GRPR
SSTR
ER
PR
HER2
author_facet Simone U. Dalm
John Fred Verzijlbergen
Marion De Jong
author_sort Simone U. Dalm
title Review: Receptor Targeted Nuclear Imaging of Breast Cancer
title_short Review: Receptor Targeted Nuclear Imaging of Breast Cancer
title_full Review: Receptor Targeted Nuclear Imaging of Breast Cancer
title_fullStr Review: Receptor Targeted Nuclear Imaging of Breast Cancer
title_full_unstemmed Review: Receptor Targeted Nuclear Imaging of Breast Cancer
title_sort review: receptor targeted nuclear imaging of breast cancer
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2017-01-01
description Receptor targeted nuclear imaging directed against molecular markers overexpressed on breast cancer (BC) cells offers a sensitive and specific method for BC imaging. Currently, a few targets such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), somatostatin receptor (SSTR), and the gastrin releasing peptide receptor (GRPR) are being investigated for this purpose. Expression of these targets is BC subtype dependent and information that can be gained from lesion visualization is dependent on the target; ER-targeting radiotracers, e.g., can be used to monitor response to anti-estrogen treatment. Here we give an overview of the studies currently under investigation for receptor targeted nuclear imaging of BC. Main findings of imaging studies are summarized and (potential) purposes of lesion visualization by targeting these molecular markers are discussed. Since BC is a very heterogeneous disease and molecular target expression can vary per subtype, but also during disease progression or under influence of treatment, radiotracers for selected imaging purposes should be chosen carefully.
topic breast cancer
receptor targeted nuclear imaging
SPECT
PET
GRPR
SSTR
ER
PR
HER2
url http://www.mdpi.com/1422-0067/18/2/260
work_keys_str_mv AT simoneudalm reviewreceptortargetednuclearimagingofbreastcancer
AT johnfredverzijlbergen reviewreceptortargetednuclearimagingofbreastcancer
AT mariondejong reviewreceptortargetednuclearimagingofbreastcancer
_version_ 1725554231733125120